GET DAILY SIGNALSGilead Sciences (GILD) Advances +14.5% on Strong Q3 Results
Key Takeaways
- Gilead Sciences (GILD) advanced roughly 14.5% over the trailing 30 days, rising from a closing price of $149.05 on September 30, 2026, to $170.68 on October 30, 2026.
- The move was fueled primarily by a stronger-than-expected third-quarter 2026 earnings report and an upward revision to full-year guidance.
- Base business product sales grew 16% year over year, the company's strongest growth in more than a decade, driven by HIV products, Trodelvy, and Livdelzi.
- Non-GAAP diluted EPS of $2.55 beat the analyst consensus estimate of $2.17, while total product sales of $8.3 billion topped the $7.79 billion consensus.
- Over the trailing quarter, the stock has climbed roughly 30%, extending a sustained multi-month uptrend.
- For more detail on valuation, results, and expectations, explore Gilead's Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioned across the market, visit Tickeron's Trending AI Robots.
Gilead Sciences (GILD) Company Overview and Market Position
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, with more than three decades of experience developing medicines for life-threatening diseases. Its business is centered on three therapeutic areas: virology, oncology, and inflammation. In virology, Gilead's HIV franchise remains the core of its revenue, anchored by Biktarvy and Descovy, alongside treatments for viral hepatitis. The company's oncology portfolio is led by Trodelvy, a Trop-2-directed antibody-drug conjugate used in breast cancer, and a growing cell therapy business operated through Kite. In inflammation, Gilead is advancing a broad pipeline that includes Livdelzi, approved for primary biliary cholangitis. I keep an eye on GILD because of its durable HIV cash flows, a maturing oncology franchise, a substantial dividend, and an active pipeline of potential launches.
Gilead Sciences (GILD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, GILD moved from a closing price of $149.05 on September 30, 2026, to $170.68 on October 30, 2026, a gain of approximately 14.5%. The advance was not linear: the stock drifted lower into early October, touching a near-term low near $144 before recovering through the middle of the month and accelerating sharply after third-quarter results were released on October 29.
The quarterly picture is even stronger. From a closing level of $131.28 on July 30, 2026, the stock has risen to $170.68, a gain of roughly 30% over the trailing three months. This reflects a sustained upward trend rather than an isolated event, as improving fundamentals and repeated guidance increases have steadily supported the shares. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the stock compares to others in the industry.
What Drove GILD Stock Price in the Last 30 Days
The dominant catalyst over the past month was Gilead's third-quarter 2026 earnings release on October 29. The company reported total product sales of $8.3 billion, up 13% year over year, and non-GAAP diluted EPS of $2.55, well ahead of the $2.17 consensus estimate. Excluding the COVID-19 treatment Veklury, base business sales rose 16%, the strongest year-over-year growth in more than a decade.
Strength was broad-based. HIV product sales increased 18% to $6.2 billion, with Biktarvy reaching $4.1 billion in quarterly sales and Descovy climbing 49% to $1.0 billion. Oncology showed momentum as Trodelvy sales rose 42% to $506 million, reaching an approximately $2 billion annual run rate, while Livdelzi grew 93% to $203 million. Management again raised full-year guidance, lifting total product sales expectations to $31.0 billion to $31.3 billion. Investors also noted the declaration of a $0.82 quarterly dividend, reinforcing Gilead's shareholder-return profile. These results, combined with pre-earnings accumulation in the shares, drove the sharp two-day advance into month-end.
What Drove GILD Stock Performance Over the Last Quarter
Gilead's roughly 30% gain over the trailing quarter reflects a larger narrative of renewed business momentum and pipeline progress. Throughout 2026, the company has repeatedly raised its base business revenue guidance, cumulatively by $1.6 billion, as HIV demand, HIV prevention uptake, and oncology growth outpaced expectations. HIV prevention in particular has accelerated, with Descovy and the injectable Yeztugo expanding the PrEP franchise.
The quarter also featured meaningful strategic activity, including acquisitions and agreements such as the PepStar oral IL-23R inhibitor program, positive Phase 2 data for emvistegrast in ulcerative colitis, and European approval of Trodelvy in first-line metastatic triple-negative breast cancer. Investor attention has increasingly focused on the pipeline, including the potential approval of anito-cel in multiple myeloma, positioning Gilead for the next wave of product launches.
GILD Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will monitor several factors that could influence GILD's trajectory. Key clinical and regulatory milestones include the December 23, 2026 PDUFA date for anito-cel in multiple myeloma and continued updates from the inflammation and HIV pipelines. The Biktarvy Medicare Maximum Fair Price, set at $2,600 per 30-day supply, is expected to create an estimated $1.5 billion net revenue impact beginning in 2028, a headwind that management has flagged but that remains outside the near-term window.
Additional areas to watch include HIV inventory dynamics, which management expects to normalize by year-end, competitive pressures in cell therapy, and the integration of recent acquisitions. Macroeconomic factors such as interest rates, healthcare policy, and broader sector rotation into and out of biopharmaceuticals may also influence sentiment. As always, these factors should be considered alongside Gilead's fundamental performance rather than as a basis for any specific investment decision. From what I see, I’m watching this closely for updates on the pipeline.
Exploring Tickeron AI Tools for Market Analysis
In my own research process, I find Tickeron’s AI Daily Buy/Sell Signals helpful for spotting potential entry and exit points across a range of tickers, including those in the healthcare sector. The platform also offers AI Pattern Search Engine for identifying technical setups that align with fundamental catalysts like the ones seen in recent earnings. These resources complement traditional analysis by providing data-driven perspectives that can inform position sizing and timing decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for GILD turns positive, indicating new upward trend
GILD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 57 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GILD just turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 35 of 54 cases over the following month. The odds of a continued upward trend are 65%.
Following a +7.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 216 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 129 of 264 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.856) is normal, around the industry mean (-1.376). GILD's P/E Ratio (-65.261) is considerably lower than the industry average of (21.842). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.039) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor
Advertisement